NCT00886795

Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy

A Phase I/II Open-label Study to Evaluate The Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy.

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: Johns Hopkins University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study is being done to find out if a drug called Abatacept (Orencia ®) is safe and effective in treating people with chronic urticaria (persistent hives).

Conditions

• Urticaria

Interventions

Type	Name	Description
DRUG	abatacept (Orencia ®)	4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 week, and 8 weeks.

Timeline

• Start date: 2009-05-01
• Primary completion: 2013-03-01
• Completion: 2013-03-01
• First posted: 2009-04-23
• Last updated: 2016-01-25
• Results posted: 2016-01-25

Locations

1 site across 1 country: United States